Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

151.35 +2.74 (+1.84%)

Streaming Delayed Price Updated: 12:22 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

56 57 Next >

AI Takes Center Stage in Biodefense: DARPA's NODES Program Promises to Revolutionize Pandemic and Biowarfare Protection

September 25, 2025

In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July...

Via MarketMinute

Topics Artificial Intelligence

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗

September 25, 2025

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Via Benzinga

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies ↗

September 24, 2025

A judge upholds Maine's contract pharmacy law, rejecting drugmakers' claims that it conflicts with federal rules governing the 340B drug discount program.

Via Benzinga

Monte Rosa Therapeutics Stock Scores Biggest Gain In Nearly A Year On $5.7B Novartis Deal For Immune-Mediated Diseases ↗

September 15, 2025

Via Stocktwits

Google DeepMind Chief Eyes Radical AI-Powered Shift In Drug Discovery Speed — Eli Lilly, Novartis Are Already Onboard ↗

September 12, 2025

Via Stocktwits

Why Is Avidity Biosciences Stock Down 20% Pre-market Today? ↗

September 11, 2025

Via Stocktwits

Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened ↗

September 09, 2025

Via Stocktwits

Scholar Rock's Spinal Muscular Atrophy Drug Faces FDA Delay Over Catalent Indiana Inspection ↗

September 23, 2025

FDA cites Catalent Indiana issues in Scholar Rock's SMA drug review; European approval decision expected in 2026, with Germany as the launch market.

Via Benzinga

Roche Targets Top Spot In Weight Loss Drug Market ↗

September 22, 2025

Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions.

Via Benzinga

Novartis Builds US Drug Reserves Against Potential Tariffs ↗

September 22, 2025

Novartis bolsters U.S. drug reserves and plans $23 billion in investments as CEO Vas Narasimhan addresses tariff risks and trade policy uncertainty.

Via Benzinga

Topics World Trade

Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery...

Via MarketMinute

Topics Animal Testing Artificial Intelligence Intellectual Property

Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’ ↗

September 02, 2025

Via Stocktwits

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments ↗

September 15, 2025

Monte Rosa's stock jumps as it partners with Novartis to develop degraders for immune diseases, with up to $5.7 billion in payments.

Via Benzinga

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Value Investors ↗

September 15, 2025

Discover Novartis (NVS), an undervalued pharma stock with strong fundamentals, high profitability, and a solid margin of safety for value investors.

Via Chartmill

This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

September 12, 2025

Via Benzinga

Wall Street Cheers Nebius-Microsoft Megadeal While Apple Misses the Mark ↗

September 10, 2025

U.S. markets closed higher on Tuesday, buoyed by fresh labor data signaling a cooling job market—potentially paving the way for Fed rate cuts. Nebius soared nearly 50% on a multibillion-dollar AI-cloud...

Via Chartmill

Topics Economy

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz ↗

September 09, 2025

Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential...

Via Benzinga

Topics ETFs Government

Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense' ↗

September 09, 2025

Novartis agreed to buy a cardiovascular-focused biotech company

Via Investor's Business Daily

Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion ↗

September 09, 2025

Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company.

Via Investor's Business Daily

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver ↗

September 09, 2025

Novartis is betting big on radioligand cancer therapy, but while the long-term growth story looks strong, NVS stock may face a short-term pullback

Via MarketBeat

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition ↗

September 09, 2025

Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardiovascular risk reduction.

Via Benzinga

2024 R&D Spending and Intensity Benchmarks

September 08, 2025

Via PRLog

Topics Supply Chain

Novartis AG (NYSE:NVS) Offers a Compelling Mix of Dividend Yield, Profitability, and Financial Health ↗

September 08, 2025

Discover Novartis (NVS), a top dividend stock with a strong 3.37% yield, high profitability, and a sustainable payout for reliable income.

Via Chartmill

1 High-Yield Vanguard Dividend Fund to Buy Hand Over Fist ↗

September 05, 2025

This international dividend powerhouse quietly delivered 26.6% returns this year -- more than doubling the S&P 500 while paying triple the income.

Via The Motley Fool

Topics ETFs Stocks

Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal ↗

September 05, 2025

The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology.

Via The Motley Fool

Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms ↗

September 04, 2025

Palantir is strengthening its role in the US industry through partnerships with Lear and Lumen and will showcase customer success stories at its AIPCon 8 event in September 2025.

Via Benzinga

Topics Artificial Intelligence

Palantir Hosts Eighth AIPCon. Stays Above 50-Day Line. Is PLTR Stock A Buy? ↗

September 04, 2025

Palantir stock bulls tout the software maker's AI strategy and strong U.S. government business amid a lofty valuation for PLTR stock.

Via Investor's Business Daily

Topics Artificial Intelligence ETFs Government

Why Did Bollinger Innovations Stock Plunge 18% Today? ↗

September 02, 2025

The company stated that it has eliminated third-party manufacturing, specifically with Roush Industries, and has instead consolidated the B4 production line from Roush Industries to the company-owned...

Via Stocktwits

Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion ↗

September 02, 2025

Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.